
Keywords: Bioavailability; Functional foods; Human trial; Hypercholesterolaemia; Isoflavones; Soy flour; CHD; coronary heart disease; CON; control; DWSF; de-fatted whole soy flour; EFSA; European Food Safety Authority; HDS; high-dose soy; LDS; low-dose soy; LPH; la